“The company is preparing to launch a dedicated heterologous booster trial, which will evaluate a VLA2001 booster shot provided at least six months after primary vaccination with other vaccines or following natural infection. This study is expected to commence in early 2022,” it said Thursday.
“We are extremely pleased to report our first booster data, confirming that VLA2001 significantly boosted immunity in participants who received VLA2001 as a primary vaccination and regardless of the initial neutralising antibody level at the time of boosting,” Valneva's chief medical officer Juan Carlos Jaramillo said.
“Our teams are working diligently on our rolling review regulatory submissions so that we can quickly deploy our vaccine.”
The EU's drug regulator said in early December it had started a rolling review of Valneva's vaccine — which could speed up approval — weeks after the EU signed a supply deal with the company.
Unlike shots from Pfizer-BioNTech, AstraZeneca, Johnson & Johnson and Novavax, Valneva's exposes the immune system to the entire coronavirus, not just its spike protein.
Valneva has said it is hopeful its vaccine candidate would protect people against variants of the virus, adding it would test it specifically against Omicron.